Decoy Therapeutics Inc.DCOY
What Decoy Therapeutics Inc. does.
Unless the context otherwise requires, “Company,” “we,” “us,” and “our” refer to the combined organization, Decoy Therapeutics Inc. (“Decoy”, formerly known as Salarius Pharmaceuticals, Inc. (“Salarius”)), and, where appropriate, its consolidated subsidiaries. References to “Legacy Decoy” refer to Decoy Therapeutics Inc. prior to the Merger (as defined below), which became a wholly owned subsidiary of the Company as a result of the Merger. References to “Notes” refer to the Notes to Consolidated Financial Statements included herein (refer to Item 8).
We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP 3 ACT™ platform. Our IMP 3 ACT™ platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning ("ML") and artificial intelligence ("AI") tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. Peptide conjugates are emerging as a major therapeutic drug modality, with the potential to transform multiple therapeutic areas. Utilizing our novel IMP 3 ACT platform that increases the drug development speed and reduce the complexity of variant synthesis, we aim to build a robust portfolio of novel peptide conjugate therapeutics, initially focusing on infectious diseases and oncology, with the goal of becoming a fully integrated biopharmaceutical company at the forefront of this field. Through this approach, we intend to revolutionize the design, development, and commercialization of peptide conjugate therapeutics. We have no products approved for commercial sales and have not generated any revenue from product sales.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.2M | $1.8M | $0 | — | — | — |
| Net income | -$7.4M | -$12.8M | -$31.6M | -$12.5M | -$5.6M | -$12.5M |
| Free cash flow | -$10.3M | -$10.2M | — | — | -$4.5M | -$5.4M |
More on DCOY.
- Decoy Therapeutics Inc. summary
- Decoy Therapeutics Inc. financial statements
- Decoy Therapeutics Inc. key metrics
- Decoy Therapeutics Inc. health scores and style box
- Decoy Therapeutics Inc. earnings
- Decoy Therapeutics Inc. dividends
- Decoy Therapeutics Inc. valuation
- Decoy Therapeutics Inc. ownership and insiders
- Decoy Therapeutics Inc. peers
Figures from Decoy Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.